

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>4</sup> : C12P 21/00, A61K 37/00 C12N 15/00, 1/00, C07H 15/12</p>	<p>A1</p>	<p>(11) International Publication Number: WO 86/ 05810 (43) International Publication Date: 9 October 1986 (09.10.86)</p>
<p>(21) International Application Number: PCT/US86/00579 (22) International Filing Date: 25 March 1986 (25.03.86) (31) Priority Application Number: 8507833 (32) Priority Date: 26 March 1985 (26.03.85) (33) Priority Country: GB  (71) Applicant (for all designated States except US): BIOGEN N.V. [NL/NL]; Pietermaai 15, Willemstad, Curaçao (AN). (72) Inventors; and (75) Inventors/Applicants (for US only) : BUELI, Gary, N. [US/CH]; 4, rue de Bonivard, CH-1201 Geneva (CH). MOVVA, Nageswararao [IN/CH]; 10, avenue Secheron, CH-1202 Geneva (CH). (74) Agents: HALEY, James, F., Jr. et al.; Fish &amp; Neave, 875 Third Avenue, 29th Floor, New York, NY 10022-6250 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US.  Published With international search report.</p>
<p>(54) Title: PRODUCTION OF HUMAN SOMATOMEDIN C</p> <p>(57) Abstract</p> <p>A process for selecting DNA sequences that are optimal for the production of polypeptides in hosts transformed with those DNA sequences. These DNA sequences, which code for a variety of human and animal proteins, permit the high level expression of those products in hosts cells. In the preferred embodiment of this invention, DNA sequences optimal for the production of human somatomedin C are selected and employed to express that growth enhancing factor.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	ME	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

## PRODUCTION OF HUMAN SOMATOMEDIN C

### TECHNICAL FIELD OF THE INVENTION

5 This invention relates to a process for  
identifying DNA sequences that are optimal for the  
production of any desired protein or polypeptide in  
hosts transformed with those DNA sequences. More  
particularly, it relates to the identification of  
those modified DNA sequences that are optimal for  
10 the production of human somatomedin C ("SMC"). This  
invention also relates to recombinant DNA molecules  
and hosts characterized by those DNA sequences, and  
to methods of using those DNA sequences, recombinant  
DNA molecules, and hosts to improve the production  
15 of human SMC and other proteins of prokaryotic and  
eukaryotic origin.

### BACKGROUND OF THE INVENTION

Somatomedin C ("SMC") is an insulin-like  
growth factor that appears to be the critical protein  
20 signalling tissue growth following secretion of  
growth hormone from the pituitary.

The amino acid sequence of human SMC was  
reported by E. Rinderknecht and R. E. Humble,  
J. Biol. Chem., 253, pp. 2769-76 (1978). It consists,  
25 of a single chain polypeptide of 70 amino acids,

-2-

cross-linked by three disulfide bridges. The calculated molecular weight is 7649. SMC displays extensive homology to proinsulin. For example, SMC amino acids 1 to 29 are homologous to the insulin B chain and SMC amino acids 42-62 are homologous to the insulin A chain. The connecting chain in SMC, however, shows no homology to the C peptide of proinsulin and SMC also has a C-terminal octapeptide not found in proinsulin.

SMC displays numerous growth promoting effects in vitro, such as stimulation of DNA, RNA, protein and proteoglycan synthesis [E. Rinderknecht and R. E. Humble, Proc. Natl. Acad. Sci USA, 73, pp. 2365-69 (1976); B. Morell and E. R. Froesch, Eur. J. Clin. Invest., 3, pp. 119-123 (1973); E. R. Froesch et al., Adv. Mental. Disord., 8, pp. 211-35 (1975); A. E. Zingg and E. R. Froesch, Diabetologia, 9, pp. 472-76 (1973); E. R. Froesch et al., Proc. Natl. Acad. Sci. USA, 73, pp. 2904-08 (1976)]. It also stimulates ornithine decarboxylase and cell proliferation [B. Morrel and E. R. Froesch, supra; G. K. Haselbacher and R. E. Humble, J. Cell. Physiol., 88, pp. 239-46 (1976)]. In vivo, SMC stimulates growth in rats made growth-hormone deficient by hypophysectomization [E. Schoenle et al., Nature, 296, pp. 252-53 (1982)].

Like growth hormones, SMCs are somewhat species specific. However, SMC from one species may be biologically active in another species lower in the evolutionary scale. For example, human SMC is believed to be useful in promoting growth in cattle, swine and chickens. In laboratory animals, SMC has shown growth stimulating effects similar to those of natural human growth hormone. However, SMC is thought to be advantaged over human growth hormone because SMC is a central mediator of the growth

-3-

response. Accordingly, it is a more direct regulator of growth than growth hormone.

In addition to SMC's use in treating certain forms of growth disturbances, such as dwarfism and muscle atrophy, it is also useful for stimulating tissue growth in specific areas, such as in connection with the healing of wounds, injuries and broken bones.

SMC, however, has not fulfilled its clinical potential as a tissue growth stimulator because it is available in only minute amounts through purification from human blood. Accordingly, other methods are required to overcome this lack of commercial and clinically useful quantities of SMC.

One such approach might involve the use of recombinant DNA technology to produce SMC in hosts transformed with a DNA sequence coding for it. However, this approach has not proved useful in preparing large amounts of SMC, because the expression yields of SMC in various E.coli hosts have been too low to provide economically useful or commercial quantities of SMC.

#### DISCLOSURE OF THE INVENTION

This invention solves the problems referred to above by providing a process for identifying DNA sequences that are optimal for the production of SMC, or any other desired eukaryotic or prokaryotic protein or polypeptide, in hosts transformed with those DNA sequences. The modified DNA sequences selected by this process code on expression for those proteins, particularly in the preferred embodiment of this invention, SMC, and permit the efficient high level production of them in various hosts. Accordingly, by virtue of this invention, it is for the first time possible to obtain polypeptides displaying

-4-

the growth stimulating and mediating activities of SMC in clinically useful quantities.

As will be appreciated from the disclosure to follow, in the preferred embodiment of this invention, the novel DNA sequences and recombinant DNA molecules of this invention are capable of directing the production, in appropriate hosts, of large amounts of SMC and SMC-like polypeptides. These polypeptides are then useful in a wide variety of growth stimulating and mediating activities in humans, as well as in cattle, swine and chickens.

It will therefore be appreciated that one basic aspect of this invention is the design of a process for identifying DNA sequences that are optimal for the production of SMC, or any other desired eukaryotic or prokaryotic protein or polypeptide. The second basic aspect of this invention relates to various novel DNA sequences, recombinant DNA molecules and hosts that enable the production of those proteins, and particularly SMC and SMC-like polypeptides, in improved yields.

In general outline, the process of this invention for improving the production of a desired eukaryotic or prokaryotic protein or polypeptide in a host transformed with a DNA sequence encoding for that protein or polypeptide comprises the steps of replacing a portion of the N-terminal end of a DNA sequence encoding an easily assayable protein or polypeptide with a degenerate series of DNA sequences encoding a portion of the N-terminal end of the desired eukaryotic or prokaryotic protein or polypeptide; expressing the resulting series of hybrid DNA sequences operatively linked to a desired expression control sequence in an appropriate host; selecting the particular hybrid DNA sequences that enable the optimal production of the easily assayable protein

-5-

or polypeptide and employing that portion of the N-terminal end of those selected hybrid DNA sequences that codes for the N-terminal portion of the desired polypeptide or protein in the expression of the desired polypeptide or protein. This process advantageously permits optimal production of the desired protein or polypeptide.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 displays in schematic outline one method for preparing a synthetic DNA sequence coding for f-Met-SMC and a plasmid, pLc24muSMC<sub>ori</sub>, containing that DNA sequence downstream of sequences derived from mu and a P<sub>L</sub> promoter.

Figure 2 depicts synthetic nucleotide sequences (both strands) of two fragments -- SMC A (Fragment A) and SMC B (Fragment B) -- used in one embodiment of the method of this invention to prepare a synthetic DNA sequence coding for f-Met-SMC. Figure 2 also displays the amino acid sequences of fragments SMC A and SMC B and the various oligonucleotide sequences, 1-11, X, Y and Z, used to prepare those fragments.

Figure 3 displays in schematic outline one method for preparing plasmids pUCmuSMC A<sub>ori</sub>, pUCmuSMC A 1-18 and pUCmuSMC 1-18. In the sequence of the 512-times degenerate synthetic linker depicted in the center of Figure 3, "N" designates all 4 base possibilities, "P" designates purines, and "Y" designates pyrimidines.

#### BEST MODE OF CARRYING OUT THE INVENTION

In order that the invention herein described may be fully understood, the following detailed description is set forth.

-6-

In the description, the following terms are employed:

Nucleotide -- A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose). That combination of a base and a sugar is called a nucleoside. Each nucleotide is characterized by its base. The four DNA bases are adenine ("A"), guanine ("G"), cytosine ("C") and thymine ("T"). The four RNA bases are A, G, C and uracil ("U").

DNA Sequence -- A linear array of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.

Codon -- A DNA sequence of three nucleotides (a triplet) which encodes through mRNA an amino acid, a translation start signal or a translation termination signal.

Gene -- A DNA sequence which encodes through its template or messenger RNA ("mRNA") a sequence of amino acids characteristic of a specific polypeptide.

Transcription -- The process of producing mRNA from a gene.

Translation -- The process of producing a polypeptide from mRNA.

Expression -- The process undergone by a DNA sequence or gene to produce a polypeptide. It is a combination of transcription and translation.

Plasmid -- A non-chromosomal double-stranded DNA sequence comprising an intact "replicon" such that the plasmid is replicated in a host cell. When the plasmid is placed within a unicellular organism, the characteristics of that organism may



-7-

be changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance (Tet<sup>R</sup>) transforms a cell previously sensitive to tetracycline into one which is resistant to it. A cell transformed by a plasmid is called a "transformant".

Phage or Bacteriophage -- Bacterial virus many of which consist of DNA sequences encapsidated in a protein envelope or coat ("capsid").

Cloning Vehicle -- A plasmid, phage DNA or other DNA sequence which is able to replicate in a host cell, which is characterized by one or a small number of endonuclease recognition sites at which such DNA sequence may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contains a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is often called a vector.

Cloning -- The process of obtaining a population of organisms or DNA sequences derived from one such organism or sequence by asexual reproduction.

Recombinant DNA Molecule or Hybrid DNA -- A molecule consisting of segments of DNA from different genomes which have been joined end-to-end and have the capacity to infect some host cell and be maintained therein.

Expression Control Sequence -- A sequence of nucleotides that controls and regulates expression of genes when operatively linked to those genes. They include the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage  $\lambda$ , the control region of fd coat

-8-

protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus and simian virus, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of yeast acid phosphatase, e.g., Pho5, the promoters of the yeast  $\alpha$ -mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells and their viruses, or combinations thereof.

10        SMC -- Somatomedin C

SMC-Like Polypeptide -- A polypeptide displaying a growth stimulating or mediating activity of SMC. For example, an SMC-like polypeptide may include an N-terminal methionine, or other peptide, fused to the first glycine of mature SMC. It may also include a threonine, instead of a methionine, at amino acid position 59. And, an SMC-like polypeptide may include various other substitutions, additions or deletions to the amino acid sequence of mature SMC.

20            This invention has several aspects. First, it relates to a process for improving the production of any eukaryotic or prokaryotic protein or polypeptide in a host cell transformed with a DNA sequence coding on expression for that protein or polypeptide. This invention also relates to a process for selecting DNA sequences that permit this optimal production of any eukaryotic or prokaryotic protein or polypeptide in a host cell transformed with those DNA sequences. It also relates to the DNA sequences selected by that latter process and their use in producing the proteins and polypeptides coded for by them. Finally, in one preferred embodiment, this invention relates to DNA sequences that encode SMC-like polypeptides and to processes for selecting those DNA sequences and employing them in optimizing the production of SMC in hosts transformed with them.

-9-

A wide variety of host/expression vector combinations may be utilized in our expression of both the hybrid DNA sequences of this invention and the selected DNA sequences that permit the optimal production of the desired eukaryotic or prokaryotic protein or polypeptide. For example, useful expression vectors may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences, such as various known derivatives of SV40 and known bacterial plasmids, e.g., plasmids from E.coli including Col El, pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, e.g., RP4, phage DNAs, e.g., the numerous derivatives of phage  $\lambda$ , e.g., NM 989, and other DNA phages, e.g., M13 and Filamentous single-stranded DNA phages, vectors useful in yeasts, such as the 2 $\mu$  plasmid, vectors useful in eukaryotic cells and animal cells, such as those containing SV40 derived DNA sequences, and vectors derived from combinations of plasmids and phage DNAs, such as plasmids which have been modified to employ phage DNA or other derivatives thereof.

Among such useful expression vectors are vectors that enable the expression of the cloned DNA sequences in eukaryotic hosts, such as animal and human cells (e.g., P. J. Southern and P. Berg, J. Mol. Appl. Genet., 1, pp. 327-41 (1982); S. Subramani et al., Mol. Cell. Biol., 1, pp. 854-64 (1981); R. J. Kaufmann and P. A. Sharp, "Amplification And Expression Of Sequences Cotransfected With A Modular Dihydrofolate Reductase Complementary DNA Gene", J. Mol. Biol., 159, pp. 601-21 (1982); R. J. Kaufmann and P. A. Sharp, Mol. Cell. Biol., 159, pp. 601-64 (1982); S. I. Scahill et al., "Expression And Characterization Of The Product Of A Human Immune Interferon DNA Gene In Chinese Hamster Ovary Cells",

-10-

Proc. Natl. Acad. Sci. USA, 80, pp. 4654-59 (1983);  
G. Urlaub and L. A. Chasin, Proc. Natl. Acad. Sci. USA, 77, pp. 4216-20 (1980)).

Such expression vectors are also characterized by at least one expression control sequence that is operatively linked to the particular DNA sequence in order to control and to regulate the expression of that cloned DNA sequence. Examples of useful expression control sequences are the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage  $\lambda$ , the control region of fd coat protein, the glycolytic promoters of yeast, e.g., the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, e.g., Pho5, the promoters of the yeast  $\alpha$ -mating factors, and promoters derived from polyoma, adenovirus and simian virus, e.g., the early and late promoters of SV40, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells and their viruses or combinations thereof.

Useful expression hosts include well known eukaryotic and prokaryotic hosts, such as strains of E.coli, such as E.coli HB101, E.coli XL776, E.coli X2282, E.coli DH1( $\lambda$ ), and E.coli MRC1, Pseudomonas, Bacillus, such as Bacillus subtilis, Streptomyces, yeasts and other fungi, animal, such as COS cells and CHO cells, and human cells and plant cells in tissue culture.

Of course, not all host/expression vector combinations function with equal efficiency in expressing the DNA sequences of this invention or in producing the polypeptides of this invention. However, a particular selection of a host/expression vector combination may be made by those of skill in the art after due consideration of the principles set forth herein without departing from the scope of

-11-

this invention. For example, the selection should be based on a balancing of a number of factors. These include, for example, compatibility of the host and vector, toxicity of the proteins encoded by the DNA sequence to the host, ease of recovery of the desired protein, expression characteristics of the DNA sequences and the expression control sequences operatively linked to them, biosafety, costs and the folding, form or any other necessary post-expression modifications of the desired protein.

Furthermore, within each specific expression vector, various sites may be selected for insertion of the DNA sequences of this invention. These sites are usually designated by the restriction endonuclease which cuts them. They are well recognized by those of skill in the art. It is, of course, to be understood that an expression vector useful in this invention need not have a restriction endonuclease site for insertion of the chosen DNA fragment. Instead, the vector could be joined to the fragment by alternative means. The expression vector, and in particular the site chosen therein for insertion of a selected DNA fragment and its operative linking therein to an expression control sequence, is determined by a variety of factors, e.g., number of sites susceptible to a particular restriction enzyme, size of the protein to be expressed, susceptibility of the desired protein to proteolytic degradation by host cell enzymes, contamination or binding of the protein to be expressed by host cell proteins difficult to remove during purification, expression characteristics, such as the location of start and stop codons relative to the vector sequences, and other factors recognized by those of skill in the art. The choice of a vector and an insertion site for a DNA sequence is determined by a balance of these factors, not all selections being equally effective for a given case.

-12-

Various DNA sequences encoding easily assayable proteins or polypeptides may also be used in this invention. For example, in our preferred embodiment of this invention, we employ  $\beta$ -galactosidase because the production of that protein may be easily monitored using well-known colorimetric plating assays. We could also employ others, such as galactokinase or drug resistance genes, e.g. ampicillin resistance.

Finally, the processes of this invention and the DNA sequences selected by and used in them are applicable to any prokaryotic or eukaryotic protein or polypeptide. Among these are human and animal lymphokines, including interferons, interleukins and TNFs, human and animal hormones, including growth hormones and insulins, human and animal blood factors, including factor VIII and tPA, enzymes, antigens and other proteins and polypeptides of interest. In our preferred embodiment described herein, we used the processes of this invention to optimize the production of SMC-like polypeptides.

In order that our invention herein described may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and should not be construed as limiting this invention in any way to the specific embodiments recited therein.

30      PREPARATION OF A RECOMBINANT DNA  
MOLECULE HAVING A DNA SEQUENCE CODING  
FOR AN SMC-LIKE POLYPEPTIDE

Referring now to Figure 1, we have shown therein a schematic outline of one embodiment of a process for preparing a recombinant DNA molecule (pLc24muSMC<sub>ori</sub>) characterized in that it has a DNA sequence coding for human f-Met-SMC fused to a DNA sequence derived from mu and carrying a Shine Dalgarno

-13-

sequence from mu, the combined DNA sequence being operatively-linked to a  $P_L$  promoter derived from bacteriophage  $\lambda$ .

To construct pLc24muSMC<sub>ori</sub>, we first synthesized 14 oligodeoxynucleotides (see Figures 1 and 2, Sequences 1-11, X, Y and Z) using the reported amino acid sequence of human SMC [Rinderknecht and Humble, supra; D. G. Klapper et al., Endocrinol., 112, pp. 2215-17 (1983)]. For synthesis we used the solid-phase phosphotriester method [H. Ito et al., Nucleic Acids Res., 10, pp. 1755-69 (1982)]. After deprotection of the crude oligomers, we desalted them by gel filtration on Sephadex G-50 and purified them by electrophoresis on denaturing polyacrylamide preparative slab gels containing urea [T. Maniatis et al., Biochem., 14, pp. 3787-94 (1975)]. We localized the bands by UV shadowing and isolated the oligodeoxynucleotides by electroelution from gel slices. We then phosphorylated the gel-purified oligodeoxynucleotides using  $T_4$  polynucleotide kinase and repurified them on 15% polyacrylamide/7M urea gels, recovering the DNA by electroelution [T. Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory (1982)]. Our 14 oligodeoxynucleotides varied in size from 13 to 37 bases.

In these syntheses, we considered the codon usage in highly expressed genes of E.coli [R. Grantham et al., Nucleic Acids Res., 8, pp. 1983-92 (1980)] and E.coli tRNA abundancies [T. Ikemura, J. Mol. Biol., 151, pp. 389-409 (1981)]. We also included a variety of convenient endonuclease recognition sites at various positions along our oligonucleotide sequences.

We then ligated sequences 1-4 and X, Y and Z and sequences 5-11 and elongated them with Klenow polymerase to form two composite DNA sequences -- Fragment A, a 98-base pair blunt-end fragment

-14-

("SMC A"), and Fragment B, a 138-base pair blunt-end fragment ("SMC B"). [J. R. Rossi et al., J. Biol. Chem., 257, pp. 9226-29 (1982)] (Figures 1 and 2). Fragment A codes for the N-terminal end of SMC and

5 Fragment B for the remainder of SMC (Figure 2).

We prepared fragment SMC A by heating 200 pmol each of sequences 1-4, X, Y and Z to 95°C in 20 µl reannealing buffer (50 mM Tris-HCl (pH 7.6), 10 mM MgCl<sub>2</sub>) and then slowly cooled the mixture to

10 4°C. We added dithiothreitol, ATP and T4 DNA ligase to final concentrations of 5 mM, 70 µM and 20 µ/ml, respectively, and then incubated the reaction mixture at 4°C for 10 h. After ethanol precipitation, we applied the mixture to an 8% polyacrylamide/7M urea

15 gel and eluted the 77- and 78-base pair strands. We then combined 25 pmol of each strand in 5 µl of reannealing buffer, heated the reaction mixture to 95°C and slowly cooled it to 15°C. We then added dithiothreitol, dNTPs and the Klenow fragment of DNA

20 polymerase to 5 mM, 250 µM and 2 units, respectively, and allowed the mixture to stand at room temperature for 30 min. We purified the reaction products as above and isolated 7 pmol of the 98-base pair SMC A. We prepared 20 pmole of the 114-base pair SMC B in

25 substantially the same way using 200 pmole each of sequences 5-11.

We then inserted each of these fragments into a blunt-ended M13mp8 vector prepared by restricting 2 µg RF DNA with BamHI (for Fragment A)

30 and with BamHI and HindIII (for Fragment B), repairing the staggered ends with 1 unit E.coli DNA polymerase (Klenow fragment) in the presence of the four deoxynucleotide triphosphates (dNTPs), precipitating with ethanol, and 5'-dephosphorylating with

35 calf intestinal phosphatase (20 units in 10 mM Tris-HCl (pH 9.2), 0.2 mM EDTA) for 30 min [J. Messing, Methods in Enzymology, 101, pp. 20-78 (1983)]. For



-15-

ligation we used 20 ng of the linearized vector and 0.1 pmole of the DNA fragment in 10  $\mu$ l ligation buffer and 40 units of T4 DNA polymerase at 15°C for 24 h (Figure 1).

5 When Fragment A was ligated to the blunt-ended M13mp8 vector, we obtained a recombinant phage that had reformed the BamHI sites at the ends of the SMC fragment; in addition an NcoI site (GGATCCATGG) had formed (mp8SMC A) (Figure 1). When Fragment B  
10 was ligated to the double blunt-ended M13mp8 vector, we obtained a recombinant phage that had reformed the BamHI and HindIII sites at the ends of the SMC fragment (mp8SMC B) (Figure 1).

We next transformed E.coli JM101 [J. Messing  
15 and J. Vieira, Gene, 19, pp. 269-76 (1982)] with each of these recombinant phages and plated the transformed hosts onto L-Broth plates containing 5-bromo-4-chloro-3-indolyl- $\beta$ -galactopyranoside (X-GAL). We then purified phage DNA from 24 white plaques of  
20 E.coli JM101 transformed with mp8SMC A and mp8SMC B and sequenced the DNA by dideoxy-chain termination [A. J. H. Smith, Methods in Enzymol., 65, pp. 560-80 (1980)]. We then prepared intracellular RF DNA from mp8SMC A and mp8SMC B, digested the former with NcoI/  
25 BamHI and the latter with BamHI/HindIII, and isolated the SMC-related fragments by gel electrophoresis (Figure 1).

We then mixed the two fragments (SMC A and SMC B) with a 67-base pair fragment from the ner  
30 gene of bacteriophage mu (a gift of B. Allet) [G. Gray et al., Gene, 32, in press]. This fragment consists of nucleotides 1043-96 [H. Priess et al., Mol. Gen. Genet., 186, pp. 315-21 (1982), Figure 4], preceded by a EcoRI endonuclease restriction-site  
35 and followed by an NcoI site (CCATGG); the internal ATG of the NcoI site forming a translation initiation codon. This fragment also contains a nearly optimal

-16-

ribosomal-binding site [J. Shine and L. Dalgarno, Nature, 254, pp. 34-38 (1975)]. As a result of this ligation, we isolated a 303-base pair EcoRI-HindIII fragment comprising the  $\mu$  gene fragment, SMC A and SMC B (Figure 1). The ligation was such that the ATG initiation codon of the  $\mu$  fragment's NcoI site was fused directly, and in the correct reading frame, to SMC A (Figures 1 and 2).

We introduced this fragment into pLc24 [E. Remaut et al., Gene, 15, pp. 81-93 (1981)], that we had previously restricted with EcoRI and HindIII, to produce plasmid pLc24 $\mu$ SMC<sub>ori</sub>. This plasmid is characterized by having the SMC gene and its initiating ATG under the control of the P<sub>L</sub> promoter of bacteriophage  $\lambda$  (Figure 1).

EXPRESSION OF SMC-LIKE POLYPEPTIDES  
USING PLASMID pLc24 $\mu$ SMC<sub>ori</sub>

We cotransformed E.coli HB101 [T. Maniatis et al., Molecular Cloning, (Cold Spring Harbor Laboratory) (1982)] with pLc24 $\mu$ SMC<sub>ori</sub> and pcI857, a derivative of pACYC 184 which encodes a temperature-sensitive repressor of P<sub>L</sub> [E. Remaut et al., Gene, 22, pp. 103-13 (1983)]. Because the two plasmids carry different antibiotic resistance genes -- penicillinase (pLc24 $\mu$ SMC<sub>ori</sub>) and kanamycin (pcI857) -- correctly cotransformed cultures may be selected by growth in 50  $\mu$ g/ml ampicillin and 40  $\mu$ g/ml kanamycin.

We inoculated 5-ml cultures in L-Broth, containing 50  $\mu$ g/ml ampicillin and 40  $\mu$ g/ml kanamycin, from plates containing correctly transformed E.coli HB101 (pLc24 $\mu$ SMC<sub>ori</sub>) (pcI857) and grew the cultures overnight at 28°C. We then added 2 ml of the overnight culture to 10 ml L-Broth, prewarmed to 42°C, and vigorously agitated the cultures in a 100 ml Erlenmeyer flask at 42°C for 2 h.

-17-

In order to assay for SMC-like polypeptide production, we centrifuged the cells from 1 ml aliquots of the culture ( $A_{550}=20$ ) and lysed them by boiling (100°C) for 10 min in 50 µl SDS-β-mercapto-ethanol lysis buffer [U. K. Laemmli, *Nature*, 227, pp. 680-85 (1970)]. We then assayed any SMC activity by radioimmunoassay using a commercial assay kit (Nichols Institute Diagnostics), whose standards we had previously verified with purified IGF-1 (a gift of R. Humbel). For assay we prepared our SMC containing lysates as for gel electrophoresis, diluted them at least 20-fold in the assay buffer and assayed in duplicate. We observed that human SMC, denatured under our standard lysis conditions, was as reactive in this RIA as the native hormone.

This assay demonstrated that on temperature induction, *E.coli* HB101 (pLC24muSMC<sub>ori</sub>) (pcI857) produced very little SMC activity -- 1.4 µg/ml by RIA -- and an amount undetectable by coomassie blue staining on protein gels. We accordingly estimated the level of SMC-like polypeptide production in that transformed host at only several hundred molecules per cell.

#### 25                    ATTEMPTS TO IMPROVE THE PRODUCTION                      OF SMC-LIKE POLYPEPTIDES

As a result of the very low levels of SMC-like polypeptide production using pLC24muSMC<sub>ori</sub>, we attempted to construct various other plasmids having enhanced levels of expression.

30                    In one approach, we prepared expression vectors having a DNA sequence encoding SMC fused to a DNA sequence encoding another protein. In this approach a fusion protein consisting at its amino terminal end of a non-SMC protein and at its carboxy-  
35                    terminal end of an SMC-like polypeptide was produced. Although such fusion proteins could be produced in

-18-

high yield from our vectors, they may be less preferred in animal and human treatment than f-met-SMC or SMC itself. As a result, for the most advantageous utilization, such fusion proteins require additional treatment to remove the non-SMC portions from them. Although such methods are available (see, e.g., United States patents 4,425,437, 4,338,397 and 4,366,246), they may be less preferred, except in the case of direct secretion and maturation, than the direct expression of a desired SMC-like polypeptide.

Accordingly, in a second approach to attempt to improve the production of SMC-like polypeptides, we adopted the deletion strategy that had proven useful in increasing the expression levels of bovine growth hormone and swine growth hormone. See, e.g., European patent applications 103,395 and 104,920. Using these methods, we prepared various modified SMC coding sequences that produced SMC-like polypeptides characterized by amino-terminal deletions. For example, we prepared expression vectors, that produced an f-Met- $\Delta$ 3-SMC and an f-Met- $\Delta$ 6-SMC. Although the level of production of these modified SMC's was slightly higher than the level of production of the f-Met-SMC from vector pLc24muSMC<sub>ori</sub>, the expression levels were still very low.

Finally, in a third approach we employed various combinations of promoters and ribosome binding sites to control the expression of our SMC coding sequence. However, if anything, these modifications were worse in terms of SMC production than pLc24muSMC<sub>ori</sub>.

-19-

SELECTION OF OPTIMAL DNA SEQUENCES  
CODING FOR THE PRODUCTION OF  
SMC-LIKE POLYPEPTIDES

Because the two approaches described previously were either unsuccessful or led to the production in many cases of a less preferred form of an SMC-like polypeptide, we decided to design an approach that might allow us to select optimal sequences coding for the production of any protein, and more particularly to select the optimal DNA sequences coding for the production of SMC-like polypeptides.

This approach was based on our hypothesis that silent mutations in the DNA sequences encoding the N-terminal portion of any gene, and in the particular embodiment described in this Example, the gene coding for f-Met-SMC, might provide improved RNA secondary structure and therefore lead to higher levels of expression in a chosen host. However, because of the many possible silent mutations that would have to be analyzed to determine what effect, if any, they might have on expression in order to select the optimal coding sequences, we needed to design a quick and simple screening method for such sequences. Without such methods, clone screening would be laborious, if not virtually impossible, and the method would fail.

Gene fusions with lacZ had been used previously to monitor the production of proteins in the absence of assays for their gene products [L. Guarente et al., Cell, 20, pp. 543-53 (1980); B. A. Castilho et al., J. Bacteriol., 158, pp. 488-95 (1984)]. Moreover,  $\beta$ -galactosidase production may be easily monitored using colorimetric plating assays. Accordingly, we decided to employ this screening method to select our optimal DNA coding sequences. Of course, it should be understood that other

-20-

screening methods, albeit less preferred, are also useful in selecting the optimal DNA sequences of this invention.

To vary the secondary structure of the SMC coding sequence in this illustrative embodiment of the methods of our invention, we prepared a series of synthetic linkers that comprised the 256 possible DNA sequences encoding amino acids 2-6 of SMC. Although amino acids 2-6 of SMC can be encoded by 256 different sequences, we used a 512-times degenerate linker (Figure 3) to allow for all possible leucine codons (SMC position 5), including TTY which encodes phenylalanine. It should, of course, be understood that longer or shorter oligonucleotides could also have been used in the methods of this invention. For example, longer synthetic linkers, for example, those encoding up to SMC amino acid 20, could be usefully employed to determine the effect of those longer sequences on expression of SMC. The redundant DNA sequences of our series of 512-linkers is depicted in Figure 3.

Referring now to Figure 3, we have depicted therein one embodiment of a method of employing these redundant DNA sequences in SMC production. As displayed in Figure 3, we first subcloned the 165-base pair EcoRI-BamHI fragment of pLc24muSMC<sub>ori</sub> into EcoRI-BamHI-cleaved pUC8 to produce an in-phase fusion between lacZ and SMC at the BamHI site. We designated this vector pUCmuSMCA<sub>ori</sub> (Figure 3). We selected pUC8 because of its small size and its unique restriction sites which interrupt lacZ and lacI-host. However, it should be understood that other plasmids carrying a lacZ gene could also have been used in our screening process.

Because we made our fusion by inserting the SMC coding sequences into the promoter proximal region of the lacZ gene, expression of the hybrid

-21-

gene is under the control of the lac promoter of pUC8.

Ribosomes can initiate translation in pUCmuSMCA<sub>ori</sub> at the lac ribosome-binding site. However, such translation will quickly terminate at the in-frame stop codons of the mu fragment derived from pLc24muSMC<sub>ori</sub>. Alternatively, the ribosomes can initiate translation at the mu ribosome binding site to produce a fusion protein consisting of an amino-terminal portion from SMC and a carboxy-terminal portion from lacZ. The SMC- $\beta$ -galactosidase fusion in pUCmuSMCA<sub>ori</sub> contained 35 amino acids of SMC at the N-terminus.

Although the fusion gene in pUCmuSMCA<sub>ori</sub> is in phase, when we transfected E.coli JM83 [J. Vieira and J. Messing, Gene, 19, pp. 259-68 (1982)] with the plasmid and cultured the transformed host on LB-agar plates containing 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-GAL), we observed only white colonies after 16 h at 37°C. While these colonies eventually became very pale blue after 40 h, their white color after 16 h demonstrates that they were producing very little of the SMC- $\beta$ -gal fusion protein. This result is, of course, consistent with our previously observed low expression level in pLc24muSMC<sub>ori</sub>.

We then introduced into plasmid pUCmuSMCA<sub>ori</sub> each of our collection of 512-times degenerate synthetic DNA linkers (AvaII-HaeII fragments), encoding amino acids 2-6 of SMC as a replacement for the coding sequences for those amino acids in the original plasmid. We did not phosphorylate these linkers prior to ligation in order to avoid linker concatemers. We introduced these sequences into plasmid pUCmuSMCA<sub>ori</sub> by ligating each with the fragment encoding the mu ribosome binding site plus SMC amino acid 1 (the 70 bp EcoRI-AvaII fragment of pUCmuSMCA<sub>ori</sub>) and the fragment encoding

-22-

amino acids 7-32 of SMC (the 71 bp HaeII-BamHI fragment of pUCmuSMCA<sub>ori</sub>) and then inserting the resulting EcoRI-BamHI combination fragment into EcoRI-BamHI restricted pUCmuSMCA<sub>ori</sub> (See Figure 3).

- 5 We plated 5000 colonies of E.coli JM83, that we had transformed with the above mixture of plasmids, onto L-Broth plates containing X-GAL. Approximately 10% of the resulting colonies were darker blue than pUC8muSMCA<sub>ori</sub> after 40 h at 37°C.
- 10 We then analyzed 14 (both blue and white) of the 5000 colonies (E.coli JM83 (pUCmuSMCA 1-14)) by a variety of methods: DNA sequencing of the degenerate region,  $\beta$ -galactosidase enzymatic activity, and SMC expression in E.coli C600 [T. Maniatis et al.,
- 15 Molecular Cloning (Cold Spring Harbor Laboratory) (1982)] after substitution of the 165 bp EcoRI-BamHI fragment of each of pUCmuSMCA 1-14 into pLc24muSMC<sub>ori</sub>. These latter plasmids are designated pLc24muSMC 1-18 in Figure 3. Of the fourteen
- 20 colonies selected for analysis, 10 were blue and 4 were white on the X-GAL plates. Table I displays the results of these various analyses:



-23-

TABLE I

	plasmid		2	3	4	5	6	pUC8 fusion units $\beta$ -gal*	pL plasmid $\mu$ g/ml SMC OD <sub>20</sub> lysate
			pro.	glu.	thr.	leu.	cys		
5	original 2-6 sequence pUCmuSMCA <sub>ori</sub>		CCA	GAA	ACC	CTG	TGC	0.4	1.4
10	blue colonies pUCmuSMCA	1	CCC	GAA	ACT	CTG	TGT	3.1	33
		2	CCT	GAA	ACT	TTG	TGC	2.6	45
		3	CCA	GAG	ACG	TTG	TGC	0.9	35
		4	CCA	GAG	ACG	TTG	TGT	0.9	43
		5	CCT	GAA	ACT	TTG	TGT	2.9	33
15		6	CCT	GAG	ACG	TTG	TGT	1.2	58
		7	CCG	GAA	ACG	TTA	TGT	1.9	50
		8	CCG	GAA	ACA	TTG	TGT	1.2	65
		9	CCA	GAA	ACG	TTG	TGT	1.1	32
		10	CCT	GAG	ACT	CTA	TGT	2.3	42
20	white colonies pUCmuSMCA	11	CCC	GAA	ACC	CTC	TGT	<0.1	0.10
		12	CCT	GAA	ACC	CTC	TGT	<0.1	0.11
		13	CCG	GAA	ACC	CTC	TGT	<0.1	0.10
		14	CCA	GAA	ACC	CTC	TGT	<0.1	0.09

25

\* We assayed for  $\beta$ -galactosidase activity with o-nitrophenyl- $\beta$ -D-galactoside (ONPG), substantially as described in J. H. Miller, Experiments in Molecular Genetics (Cold Spring Harbor Laboratories) (1972).

-24-

As depicted in Table I, the blue colonies, containing pUC8muSMCA 1-10, produced 2.5-8 times more units of  $\beta$ -galactosidase than E.coli JM83 (pUC8muSMCA<sub>ori</sub>). In contrast, the white colonies, containing pUCmuSMCA 11-14, produced no detectable  $\beta$ -galactosidase. Surprisingly, although the  $\beta$ -galactosidase production of pUC8muSMCA 1-10 was 2.5-8 times higher than the parental plasmid, when the EcoRI-BamHI fragments from these plasmids were inserted into pLc24muSMC<sub>ori</sub>, plasmids were generated that in E.coli HB101 produced 23-46 times more SMC activity than the parental plasmid. There was also no apparent specific correlation between units of  $\beta$ -galactosidase for a given fusion and  $\mu$ g of SMC for the corresponding expression under P<sub>L</sub> control. However, the blue/white difference of the colonies on X-GAL plates did plainly enable the selection of DNA sequences that coded for high expressors of SMC. Accordingly, this method may be employed generally to selected optimal DNA sequences for the production of any desired eukaryotic or prokaryotic polypeptide.

While not wishing to be bound by theory, we believe that the different expression levels displayed by our degenerate DNA sequences are related to the RNA secondary structure of the nucleotides that encode the N-terminal amino acids of SMC. For example, our results indicate that the possible CCC, formed by the codons for threonine-leucine (ACN-CTN) (SMC positions 4 and 5), is particularly deleterious to SMC synthesis. All of our analyzed white colonies and pUCmuSMC<sub>ori</sub> were characterized by this sequence which could form hydrogen bonds with the ribosome binding site in pLc24muSMC.

Although in the embodiment of our invention described above, we employed a DNA sequence coding for our desired protein-lac Z fusion that produced a fusion protein having 35 amino acids of SMC at the

-25-

N-terminal end, the relative lengths of the two parts of the fusion protein must be determined empirically for most effective screening in our method. Our experimental results have identified some of the factors that should be considered in making this choice. For example, ribosome binding site strength is important. When we used a trp ribosome-binding site instead of that from mu, our fusions that contained 35 amino acids of SMC did not produce blue colonies. The relative portions of  $\beta$ -galactosidase and the selected protein in the fusion protein are also important. For example, gene fusions that generated fusion proteins having only 14 SMC amino acids at the N-terminal did not allow blue/white selection. In that case, apparently the  $\beta$ -galactosidase activity of the fusion protein was too high to allow detection of optimal N-terminal coding sequences. Finally, the sensitivity of the detection system is important. We determined that the  $\beta$ -galactosidase activity range that was useful in our screening was 1-8% of the level of  $\beta$ -galactosidase produced by the original pUC8. With due consideration of these factors, and others that may similarly be determined as we have described above, one of skill in the art can select the appropriate fusion protein and assay for screening by the methods described herein without departing from the scope of this invention.

Although the specific SMC-like polypeptide produced in the above-illustrative example is an f-Met-SMC, it should be understood that the f-Met may be removed from the SMC by a variety of available means.

The SMC-like polypeptides produced by the methods of this invention can be formulated using conventional methods into pharmaceutically useful

-26-

compositions. These compositions comprise a pharmaceutically effective amount of the SMC-like polypeptide to effect the desired tissue growth stimulation and preferably a pharmaceutically acceptable carrier.

5 Suitable carriers are well known. As previously stated, the compositions are then useful in methods for stimulating tissue growth and in the treatment of dwarfism, muscle atrophy, broken bones, wounds or other injuries to tissue.

10 Microorganisms and recombinant DNA molecules prepared by the processes described herein are exemplified by cultures deposited in the culture collection Deutsche Sammlung von Mikroorganismen in Göttingen, West Germany on March 23, 1985 and identified as SMC-1 and SMC-2

SMC-1: E.coli HB101 (pcI857) (pLc24muSMC<sub>ori</sub>)

SMC-2: E.coli HB101 (pcI857) (pLc24muSMC 8)

These cultures were assigned accession numbers DSM 3276 and 3277, respectively.

20 While we have hereinbefore described a number of embodiments of this invention, it is apparent that our basic constructions can be altered to provide other embodiments which utilize the processes and compositions of this invention. Therefore, it will be appreciated that the scope of this  
25 invention is to be defined by the claims appended hereto rather than by the specific embodiments which have been presented hereinbefore by way of example.

-27-

We claim:

1. A process for improving the production of a desired polypeptide in a host transformed with a DNA sequence coding for that polypeptide and operatively linked to an expression control sequence comprising the steps of replacing a portion of the N-terminal end of a DNA sequence encoding an easily assayable polypeptide with a degenerate series of DNA sequences encoding a portion of the N-terminal end of the desired polypeptide, the replacement not substantially affecting that assayability; expressing the resulting series of hybrid DNA sequences operatively linked to the desired expression control sequence in the host; selecting the particular hybrid DNA sequences that enable the optimal production of the easily assayable polypeptide; and employing that portion of the N-terminal end of those selected hybrid DNA sequences that codes for the N-terminal portion of the desired polypeptide in the expression of that polypeptide.
2. The process according to claim 1, characterized in that said easily assayable polypeptide is selected from the group consisting of  $\beta$ -galactosidase, galactokinase and drug resistance markers.
3. The process according to claim 1, characterized in that the desired polypeptide is selected from the group consisting of interferons, interleukins and other lymphokines, blood factors, enzymes, viral antigens, SMC, growth hormones and other hormones and other polypeptides of animal and human origin.

-28-

4. The process according to claim 1, characterized in that the expression control sequence is selected from the group consisting of the lac system, the trp system, the tac system, the trc system, the major operator and promoter regions of phage  $\lambda$ , the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus and simian virus, and the promoters of yeast glycolytic enzymes,  $\alpha$ -mating factors and acid phosphatase.

5. The process according to claim 1, characterized in that said host is selected from the group consisting of strains of E.coli, Pseudomonas, Bacillus, Streptomyces, yeasts, other fungi, animal cells and plant cells.

6. The process according to claim 1, characterized in that said DNA sequence codes for an SMC-like polypeptide and is selected from the DNA inserts of pLC24muSMC 1 through pLC24muSMC 10.

7. A DNA sequence encoding a desired polypeptide produced by a process comprising the steps of replacing a portion of the N-terminal end of a DNA sequence encoding an easily assayable polypeptide with a degenerate series of DNA sequences encoding a portion of the N-terminal end of the desired polypeptide, the replacement not substantially affecting that assayability; expressing the resulting series of hybrid DNA sequences operatively linked to a desired expression control sequence in a host; selecting the particular hybrid DNA sequences that enable the optimal production of the assayable polypeptide; and replacing the N-terminal portion of a DNA sequence encoding the desired protein with that portion of the N-terminal end of those selected hybrid

-29-

DNA sequences that codes for that N-terminal portion of the desired polypeptide.

8. The DNA sequence according to claim 7, characterized in that it codes for a polypeptide selected from the group consisting of interferons, interleukins and other lymphokines, blood factors, enzymes, viral antigens, SMC, growth hormones and other hormones and other polypeptides of animal and human origin.

9. The DNA sequence according to claim 8, characterized in that it codes for an SMC-like polypeptide and is selected from the DNA inserts of pLC24muSMC 1 through pLC24muSMC 10.

10. An SMC-like polypeptide coded for on expression by a DNA sequence selected from the DNA inserts of pLC24muSMC 1 through pLC24muSMC 10.

11. A recombinant DNA molecule characterized by a DNA sequence according to claim 7.

12. The recombinant DNA molecule according to claim 11, wherein said DNA sequence is operatively linked to an expression control sequence in said recombinant DNA molecule.

13. The recombinant DNA molecule according to claim 12, wherein the expression control sequence is selected from the group consisting of the lac system, the trp system, the tac system, the trc system, the major operator and promoter regions of phage  $\lambda$ , the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus and simian virus, and the

-30-

promoters of yeast glycolytic enzymes,  $\alpha$ -mating factors and acid phosphatase.

14. The recombinant DNA molecule according to claim 13, selected from the group consisting of pLC24muSMC 1 through pLC24muSMC 10.

15. A host transformed with at least one recombinant DNA molecule according to claim 11.

16. A process for producing a desired polypeptide characterized by the step of culturing a host transformed by a recombinant DNA molecule according to claim 11.

17. A process for producing an SMC-like polypeptide characterized by the step of culturing a host transformed by a recombinant DNA molecule according to claim 14.

18. The process according to claim 17, characterized in that said host is selected from the group consisting of strains of E.coli, Pseudomonas, Bacillus, Streptomyces, yeasts, other fungi, animal cells and plant cells.

19. The process according to claim 18, characterized in that the transformed host is E.coli HB101 (pCI857) (pLC24muSMC 8).

20. An SMC-like polypeptide produced by the process according to claim 17.

21. A pharmaceutical composition characterized by an amount of an SMC-like polypeptide according to claim 20 effective as a tissue growth stimulator and a pharmaceutically acceptable carrier.



-31-

22. A method for stimulating tissue growth in mammals characterized by the step of treating a mammal with a pharmaceutical composition according to claim 21.

23. The use of a pharmaceutically effective amount of an SMC-like polypeptide according to claim 20 for stimulating tissue growth.

1/3




FIG. 1

SUBSTITUTE SHEET

2/3

# Fragment A

NcoI AvalI HaeII PstI BamHI  
 15' TCCATGGATCCAGAACCCCTGTCGGCGCTGAGCTGGAGCTTCGCTGCGGTGACCTGCGATTCACACAAACCGACTGGTTACGG SMC 3  
 13' TGGTACCCAGGCTCTTGGGACACCGCCGCGACTCGACCTCGGAGACGTCAGGACACCGCCACCTGCGCACCCTAAGATGAAGTGTTCGCTGACCAATGCC SMC 100  
 MetGlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGlnPheValCysGlyAspArgGlyPheIleProAsnLysProIleGlyIleGly

# Fragment B

BamHI HinfI/SalI HinfIII  
 15' ATCTCTCTCGAGCGCTGCTCTCAGACTGGAACTCGACGAAATGTTTCCGTTCTTGGCAGCTGAGCGGTCTAGAAATGTACTGCGCGCGCCCTGAAACCGCGGAGAGATCCATAAGCTT SMC 5  
 101 13' TAGGAGGAGCTCCGCGACGAGAGTCTGACCTTAGCAGCTGCTTACACAAGGCGAAGACGCTGGACTCCGCGAGATCTTTACATGACCGCGCGGAGCTTTGGCCGCTTCTCAGGTATTCGAA SMC 222  
 SerSerSerArgArgAlaProGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgGluGluMetIleCysAlaProLeuLysProAlaLysSerAlaGln

FIG. 2

SUBSTITUTE SHEET

3/3




FIG. 3

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US86/00579

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (4): C12P 21/00 A61K 37/00 C12N 15/00, 1/00 C07H 15/12		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
U.S.	435/68, 172.3, 317 935/9, 10,13,36,33,39,45,47 536/27 514/12 530/303, 324	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
Computer Search Chemical Abstracts, Biosis, Medline 1966 to Present: Somatomedin C, N-Terminal, Modified, Mutant, degenerate		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> **		
Category *	Citation of Document, ** with Indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
Y	<u>Proc. Natl. Acad. Sci.</u> , Vol. 73, issued 1976 (Rinderknecht et al,) pp. 2365-2369 "Poly peptides with non-suppressible insulin- like and cell-growth promoting activities in human serum: Isolation, Chemical Character- ization, and some biological properties of forms I and II" See pages 2368-2639 in particular	S 20-23
X	<u>Nucleic Acids Research</u> , Vol. 13 No. 6, issued March 25, 1985 pp. 1923-1938 (Buell et al,) "Optimizing the expression in <i>E.</i> <i>coli</i> of a synthetic gene encoding somato- medin-C (IGF-I)" See the entire article.	S 1-23
Y,P	<u>Nucleic Acids Research</u> , Vol. 13 No. 8 issued April 25, 1985 pp 2959-2977 (Sproat et al,) "Chemical Synthesis of a gene for somatomedin C" See page 2961 in particular	S 7-23
Y,P	<u>Gene</u> Vol. 35 No. 1, issued 1985 pp 83-89, (Peters et al, "Expression of a biologi-	S 7-23
<p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu- ments, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search *	Date of Mailing of this International Search Report *	
08 June 1986	19 JUN 1986	
International Searching Authority *	Signature of Authorized Officer **	
ISA/US	Robin L. Teskin <i>Robin L. Teskin</i>	

Form PCT/ISA/210 (second sheet) (October 1981)

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	<p>cally active analogue of somatomedin-C insulin like growth factor I" see page 85 in particular.</p> <p>Cell Vol. 20, issued June 1980, pp. 543-553, (Guarente et al) "Improved methods for maximizing expression of a cloned gene: a bacterium that synthesizes rabbit B-globin" See pages 518-519</p>	S 1-8
---	---	-------

V ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>10</sup>

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers \_\_\_\_\_, because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:
2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:

VL ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>14</sup>

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
Y	<u>Journal of Bacteriology</u> Vol. 158 No. 2 Issued May, 1984, pp. 488-495, (Guarente et al, "Plasmid insertion mutagenesis and lac gene fusion with mini-mu bacterio- phage transposons" see page 488.	S 1-8
Y	<u>Nucleic Acids Research</u> Vol. 8 No. 9, issued May 10, 1980, pp 1893-1912, (Grantham et al,) "Codon frequencies in 119 individual genes confirm consistent choices of degenerate bases according to genome type" See page 1893-1996	S 1-8
Y	<u>Journal of Biological Chemistry</u> Vol. 257 No. 6, Issued March 25, 1982, pp 3026- 3031, (Bennetzen et al,) "Codon selection in yeast" See pages 3030-3031	S 1-8